HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Risk Communication Panel’s Charter Is Tweaked As Members Are Named

This article was originally published in The Tan Sheet

Executive Summary

FDA is modifying the charter for its Risk Communication Advisory Committee to reflect new powers the agency gained as part of the passed FDA reauthorization bill

You may also be interested in...



FDA Template Good For Firms’ Recall Announcements – Consultant

FDA should request that firms use a proposed template for the agency's recall announcements to communicate their recalls to the public, a consultant said at the first meeting of the Risk Communications Advisory Committee

FDA Risk Committee To Consider Whether Earlier Information Is Really Better

FDA is scrutinizing how it can make timely releases of safety information without sacrificing completeness and accuracy

Risk Communication Advisory Committee

FDA is requesting nominations for membership to its new advisory committee. Comprising 15 voting members, the committee will advise the agency on ways to better communicate the risks and benefits of FDA-regulated products. FDA formed the advisory group in response to recommendations by the Institute of Medicine's 2006 report, "The Future of Drug Safety: Promoting and Protecting the Health of the Public"...

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS138359

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel